1. Home
  2. MIRM vs LBRDK Comparison

MIRM vs LBRDK Comparison

Compare MIRM & LBRDK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

HOLD

Current Price

$89.49

Market Cap

5.4B

Sector

Health Care

ML Signal

HOLD

Logo Liberty Broadband Corporation Class C

LBRDK

Liberty Broadband Corporation Class C

HOLD

Current Price

$53.38

Market Cap

6.4B

ML Signal

HOLD

Company Overview

Basic Information
Metric
MIRM
LBRDK
Founded
2018
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Cable & Other Pay Television Services
Sector
Health Care
Telecommunications
Exchange
Nasdaq
Nasdaq
Market Cap
5.4B
6.4B
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
MIRM
LBRDK
Price
$89.49
$53.38
Analyst Decision
Strong Buy
Analyst Count
12
0
Target Price
$112.00
N/A
AVG Volume (30 Days)
601.2K
1.1M
Earning Date
05-18-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
74.59
N/A
EPS
N/A
N/A
Revenue
$19,138,000.00
N/A
Revenue This Year
$24.61
N/A
Revenue Next Year
$21.75
$109.28
P/E Ratio
N/A
$10.10
Revenue Growth
N/A
N/A
52 Week Low
$36.88
$42.10
52 Week High
$109.28
$104.00

Technical Indicators

Market Signals
Indicator
MIRM
LBRDK
Relative Strength Index (RSI) 38.78 53.82
Support Level $72.17 $52.00
Resistance Level $107.51 $57.84
Average True Range (ATR) 3.75 1.65
MACD -2.53 -0.33
Stochastic Oscillator 12.45 28.08

Price Performance

Historical Comparison
MIRM
LBRDK

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About LBRDK Liberty Broadband Corporation Class C

Liberty Broadband Corp serves in the telecommunications industry in the United States. It provides cable services to both residential andsommercial businesses through its fiber, hybrid fiber, and coaxial cable infrastructure. The services provided by the company are residential services which include video services, internet services, voice services, and mobile services, commercial services which include small, and medium business and enterprise solutions, advertising services, and other services. The reportable segments of the company are GCI Holdings, Charter. The firm derives the majority of its revenue from GCI Holdings.

Share on Social Networks: